Therapeutic targeting of senescent cells in the CNS.
Journal
Nature reviews. Drug discovery
ISSN: 1474-1784
Titre abrégé: Nat Rev Drug Discov
Pays: England
ID NLM: 101124171
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
accepted:
08
08
2024
medline:
1
10
2024
pubmed:
1
10
2024
entrez:
30
9
2024
Statut:
aheadofprint
Résumé
Senescent cells accumulate throughout the body with advanced age, diseases and chronic conditions. They negatively impact health and function of multiple systems, including the central nervous system (CNS). Therapies that target senescent cells, broadly referred to as senotherapeutics, recently emerged as potentially important treatment strategies for the CNS. Promising therapeutic approaches involve clearing senescent cells by disarming their pro-survival pathways with 'senolytics'; or dampening their toxic senescence-associated secretory phenotype (SASP) using 'senomorphics'. Following the pioneering discovery of first-generation senolytics dasatinib and quercetin, dozens of additional therapies have been identified, and several promising targets are under investigation. Although potentially transformative, senotherapies are still in early stages and require thorough testing to ensure reliable target engagement, specificity, safety and efficacy. The limited brain penetrance and potential toxic side effects of CNS-acting senotherapeutics pose challenges for drug development and translation to the clinic. This Review assesses the potential impact of senotherapeutics for neurological conditions by summarizing preclinical evidence, innovative methods for target and biomarker identification, academic and industry drug development pipelines and progress in clinical trials.
Identifiants
pubmed: 39349637
doi: 10.1038/s41573-024-01033-z
pii: 10.1038/s41573-024-01033-z
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
Hayflick, L. & Moorhead, P. S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585–621 (1961).
doi: 10.1016/0014-4827(61)90192-6
pubmed: 13905658
Lundblad, V. & Szostak, J. W. A mutant with a defect in telomere elongation leads to senescence in yeast. Cell 57, 633–643 (1989).
doi: 10.1016/0092-8674(89)90132-3
pubmed: 2655926
Harley, C. B., Futcher, A. B. & Greider, C. W. Telomeres shorten during ageing of human fibroblasts. Nature 345, 458–460 (1990).
doi: 10.1038/345458a0
pubmed: 2342578
Herbig, U., Ferreira, M., Condel, L., Carey, D. & Sedivy, J. M. Cellular senescence in aging primates. Science 311, 1257 (2006).
doi: 10.1126/science.1122446
pubmed: 16456035
Minamino, T. et al. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 105, 1541–1544 (2002).
doi: 10.1161/01.CIR.0000013836.85741.17
pubmed: 11927518
Jurk, D. et al. Postmitotic neurons develop a p21-dependent senescence-like phenotype driven by a DNA damage response. Aging Cell 11, 996–1004 (2012).
doi: 10.1111/j.1474-9726.2012.00870.x
pubmed: 22882466
Arendt, T., Rodel, L., Gartner, U. & Holzer, M. Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer’s disease. Neuroreport 7, 3047–3049 (1996).
doi: 10.1097/00001756-199611250-00050
pubmed: 9116237
McShea, A., Harris, P. L., Webster, K. R., Wahl, A. F. & Smith, M. A. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer’s disease. Am. J. Pathol. 150, 1933–1939 (1997).
pubmed: 9176387
pmcid: 1858317
Musi, N. et al. Tau protein aggregation is associated with cellular senescence in the brain. Aging Cell 17, e12840 (2018).
doi: 10.1111/acel.12840
pubmed: 30126037
pmcid: 6260915
Riessland, M. et al. Loss of SATB1 induces p21-dependent cellular senescence in post-mitotic dopaminergic neurons. Cell Stem Cell 25, 514–530.e518 (2019).
doi: 10.1016/j.stem.2019.08.013
pubmed: 31543366
pmcid: 7493192
Bhat, R. et al. Astrocyte senescence as a component of Alzheimer’s disease. PLoS ONE 7, e45069 (2012).
doi: 10.1371/journal.pone.0045069
pubmed: 22984612
pmcid: 3440417
Chinta, S. J. et al. Cellular senescence is induced by the environmental neurotoxin paraquat and contributes to neuropathology linked to Parkinson’s disease. Cell Rep. 22, 930–940 (2018).
doi: 10.1016/j.celrep.2017.12.092
pubmed: 29386135
pmcid: 5806534
von Zglinicki, T., Wan, T. & Miwa, S. Senescence in post-mitotic cells: a driver of aging? Antioxid. Redox Signal. 34, 308–323 (2021).
doi: 10.1089/ars.2020.8048
Gorgoulis, V. et al. Cellular senescence: defining a path forward. Cell 179, 813–827 (2019).
doi: 10.1016/j.cell.2019.10.005
pubmed: 31675495
Munoz-Espin, D. et al. Programmed cell senescence during mammalian embryonic development. Cell 155, 1104–1118 (2013).
doi: 10.1016/j.cell.2013.10.019
pubmed: 24238962
Coppe, J. P., Desprez, P. Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99–118 (2010).
doi: 10.1146/annurev-pathol-121808-102144
pubmed: 20078217
pmcid: 4166495
Wiley, C. D. & Campisi, J. The metabolic roots of senescence: mechanisms and opportunities for intervention. Nat. Metab. 3, 1290–1301 (2021).
doi: 10.1038/s42255-021-00483-8
pubmed: 34663974
pmcid: 8889622
Nishio, K., Inoue, A., Qiao, S., Kondo, H. & Mimura, A. Senescence and cytoskeleton: overproduction of vimentin induces senescent-like morphology in human fibroblasts. Histochem. Cell Biol. 116, 321–327 (2001).
doi: 10.1007/s004180100325
pubmed: 11702190
Dehkordi, S. K. et al. Profiling senescent cells in human brains reveals neurons with CDKN2D/p19 and tau neuropathology. Nat. Aging 1, 1107–1116 (2021).
doi: 10.1038/s43587-021-00142-3
pubmed: 35531351
pmcid: 9075501
Lee, B. Y. et al. Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell 5, 187–195 (2006).
doi: 10.1111/j.1474-9726.2006.00199.x
pubmed: 16626397
Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363–9367 (1995).
doi: 10.1073/pnas.92.20.9363
pubmed: 7568133
pmcid: 40985
Bittles, A. H. & Harper, N. Increased glycolysis in ageing cultured human diploid fibroblasts. Biosci. Rep. 4, 751–756 (1984).
doi: 10.1007/BF01128816
pubmed: 6509159
Flor, A. C., Wolfgeher, D., Wu, D. & Kron, S. J. A signature of enhanced lipid metabolism, lipid peroxidation and aldehyde stress in therapy-induced senescence. Cell Death Discov. 3, 17075 (2017).
doi: 10.1038/cddiscovery.2017.75
pubmed: 29090099
pmcid: 5661608
Kuilman, T. & Peeper, D. S. Senescence-messaging secretome: SMS-ing cellular stress. Nat. Rev. Cancer 9, 81–94 (2009).
doi: 10.1038/nrc2560
pubmed: 19132009
Acosta, J. C. et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat. Cell Biol. 15, 978–990 (2013).
doi: 10.1038/ncb2784
pubmed: 23770676
pmcid: 3732483
Lopez-Otin, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. Hallmarks of aging: an expanding universe. Cell 186, 243–278 (2023).
doi: 10.1016/j.cell.2022.11.001
pubmed: 36599349
Wiley, C. D. et al. Analysis of individual cells identifies cell-to-cell variability following induction of cellular senescence. Aging Cell 16, 1043–1050 (2017).
doi: 10.1111/acel.12632
pubmed: 28699239
pmcid: 5595671
Suryadevara, V. et al. SenNet recommendations for detecting senescent cells in different tissues. Nat. Rev. Mol. Cell Biol. https://doi.org/10.1038/s41580-024-00738-8 (2024).
doi: 10.1038/s41580-024-00738-8
pubmed: 38831121
Song, Q. et al. Integrated multi-omics approach revealed cellular senescence landscape. Nucleic Acids Res. 50, 10947–10963 (2022).
doi: 10.1093/nar/gkac885
pubmed: 36243980
pmcid: 9638896
Gureghian, V. et al. A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanoma. Cancer Gene Ther. 30, 1330–1345 (2023).
doi: 10.1038/s41417-023-00640-z
pubmed: 37420093
pmcid: 10581906
Xu, P. et al. The landscape of human tissue and cell type specific expression and co-regulation of senescence genes. Mol. Neurodegener. 17, 5 (2022).
doi: 10.1186/s13024-021-00507-7
pubmed: 35000600
pmcid: 8744330
Tao, W., Yu, Z. & Han, J. J. Single-cell senescence identification reveals senescence heterogeneity, trajectory, and modulators. Cell Metab. 36, 1126–1143.e1125 (2024).
doi: 10.1016/j.cmet.2024.03.009
pubmed: 38604170
Gonzales, M. M. et al. Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial. Nat. Med. 36, 2481–2488 (2023).
doi: 10.1038/s41591-023-02543-w
Moh, C. et al. Cell cycle deregulation in the neurons of Alzheimer’s disease. Results Probl. Cell Differ. 53, 565–576 (2011).
doi: 10.1007/978-3-642-19065-0_23
pubmed: 21630160
pmcid: 5925746
Yang, Y., Mufson, E. J. & Herrup, K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer’s disease. J. Neurosci. 23, 2557–2563 (2003).
doi: 10.1523/JNEUROSCI.23-07-02557.2003
pubmed: 12684440
pmcid: 6742098
Xiong, X. et al. Epigenomic dissection of Alzheimer’s disease pinpoints causal variants and reveals epigenome erosion. Cell 186, 4422–4437.e4421 (2023).
doi: 10.1016/j.cell.2023.08.040
pubmed: 37774680
pmcid: 10782612
Mertens, J. et al. Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer’s patients. Cell Stem Cell 28, 1533–1548.e1536 (2021).
doi: 10.1016/j.stem.2021.04.004
pubmed: 33910058
pmcid: 8423435
Fujimaki, K. et al. Graded regulation of cellular quiescence depth between proliferation and senescence by a lysosomal dimmer switch. Proc. Natl Acad. Sci. USA 116, 22624–22634 (2019).
doi: 10.1073/pnas.1915905116
pubmed: 31636214
pmcid: 6842626
Lodato, M. A. et al. Aging and neurodegeneration are associated with increased mutations in single human neurons. Science 359, 555–559 (2018).
doi: 10.1126/science.aao4426
pubmed: 29217584
Abascal, F. et al. Somatic mutation landscapes at single-molecule resolution. Nature 593, 405–410 (2021).
doi: 10.1038/s41586-021-03477-4
pubmed: 33911282
Goedert, M., Clavaguera, F. & Tolnay, M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci. 33, 317–325 (2010).
doi: 10.1016/j.tins.2010.04.003
pubmed: 20493564
Gaikwad, S. et al. Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimer’s disease and frontotemporal dementia. Cell Rep. 36, 109419 (2021).
doi: 10.1016/j.celrep.2021.109419
pubmed: 34289368
pmcid: 8341760
Hussong, S. A. et al. Soluble pathogenic tau enters brain vascular endothelial cells and drives cellular senescence and brain microvascular dysfunction in a mouse model of tauopathy. Nat. Commun. 14, 2367 (2023).
doi: 10.1038/s41467-023-37840-y
pubmed: 37185259
pmcid: 10126555
Brelstaff, J. H. et al. Microglia become hypofunctional and release metalloproteases and tau seeds when phagocytosing live neurons with P301S tau aggregates. Sci. Adv. 7, eabg4980 (2021).
doi: 10.1126/sciadv.abg4980
pubmed: 34669475
pmcid: 8528424
Zhang, P. et al. Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer’s disease model. Nat. Neurosci. 22, 719–728 (2019).
doi: 10.1038/s41593-019-0372-9
pubmed: 30936558
pmcid: 6605052
Ting, K. K. et al. Vascular senescence and leak are features of the early breakdown of the blood-brain barrier in Alzheimer’s disease models. Geroscience 45, 3307–3331 (2023).
doi: 10.1007/s11357-023-00927-x
pubmed: 37782439
pmcid: 10643714
Bae, E. J. et al. TNF-alpha promotes alpha-synuclein propagation through stimulation of senescence-associated lysosomal exocytosis. Exp. Mol. Med. 54, 788–800 (2022).
doi: 10.1038/s12276-022-00789-x
pubmed: 35790884
pmcid: 9352737
Sun, J. K. et al. Chronic alcohol metabolism results in DNA repair infidelity and cell cycle-induced senescence in neurons. Aging Cell 22, e13772 (2023).
doi: 10.1111/acel.13772
pubmed: 36691110
pmcid: 9924945
Ogrodnik, M. et al. Obesity-induced cellular senescence drives anxiety and impairs neurogenesis. Cell Metab. 29, 1061–1077.e1068 (2019).
doi: 10.1016/j.cmet.2018.12.008
pubmed: 30612898
pmcid: 6509403
Chow, H. M. et al. Age-related hyperinsulinemia leads to insulin resistance in neurons and cell-cycle-induced senescence. Nat. Neurosci. 22, 1806–1819 (2019).
doi: 10.1038/s41593-019-0505-1
pubmed: 31636448
Schwab, N. et al. Neurons and glial cells acquire a senescent signature after repeated mild traumatic brain injury in a sex-dependent manner. Front. Neurosci. 16, 1027116 (2022).
doi: 10.3389/fnins.2022.1027116
pubmed: 36408415
pmcid: 9669743
Paramos-de-Carvalho, D. et al. Targeting senescent cells improves functional recovery after spinal cord injury. Cell Rep. 36, 109334 (2021).
doi: 10.1016/j.celrep.2021.109334
pubmed: 34233184
Muralidharan, A. et al. Long-term male-specific chronic pain via telomere- and p53-mediated spinal cord cellular senescence. J. Clin. Invest. 132, e151817 (2022).
doi: 10.1172/JCI151817
pubmed: 35426375
pmcid: 9012275
Razzoli, M. et al. Social stress shortens lifespan in mice. Aging Cell 17, e12778 (2018).
doi: 10.1111/acel.12778
pubmed: 29806171
pmcid: 6052478
Diniz, B. S., Reynolds Iii, C. F., Sibille, E., Bot, M. & Penninx, B. Major depression and enhanced molecular senescence abnormalities in young and middle-aged adults. Transl. Psychiatry 9, 198 (2019).
doi: 10.1038/s41398-019-0541-3
pubmed: 31434875
pmcid: 6704136
Diniz, B. S. et al. Association of molecular senescence markers in late-life depression with clinical characteristics and treatment outcome. JAMA Netw. Open 5, e2219678 (2022).
doi: 10.1001/jamanetworkopen.2022.19678
pubmed: 35771573
pmcid: 9247739
Bussian, T. J. et al. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature 562, 578–582 (2018).
doi: 10.1038/s41586-018-0543-y
pubmed: 30232451
pmcid: 6206507
Zhang, P. et al. Senolytic therapy alleviates Abeta-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer’s disease model. Nat. Neurosci. 22, 719–728 (2019).
doi: 10.1038/s41593-019-0372-9
pubmed: 30936558
pmcid: 6605052
Baker, D. J. et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530, 184–189 (2016).
doi: 10.1038/nature16932
pubmed: 26840489
pmcid: 4845101
Baker, D. J. et al. Clearance of p16
doi: 10.1038/nature10600
pubmed: 22048312
pmcid: 3468323
Zhu, Y. et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell 15, 428–435 (2016).
doi: 10.1111/acel.12445
pubmed: 26711051
pmcid: 4854923
Demaria, M. et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 7, 165–176 (2017).
doi: 10.1158/2159-8290.CD-16-0241
pubmed: 27979832
DiBattista, A. M., Sierra, F. & Masliah, E. NIA workshop on senescence in brain aging and Alzheimer’s disease and its related dementias. Geroscience 42, 389–396 (2020).
doi: 10.1007/s11357-020-00153-9
pubmed: 31933065
pmcid: 7206469
Roy, A. L. et al. A blueprint for characterizing senescence. Cell 183, 1143–1146 (2020).
doi: 10.1016/j.cell.2020.10.032
pubmed: 33128870
pmcid: 8364378
Zhu, Y. et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14, 644–658 (2015).
doi: 10.1111/acel.12344
pubmed: 25754370
pmcid: 4531078
Erlangga, Z. et al. The effect of prolonged intermittent fasting on autophagy, inflammasome and senescence genes expressions: an exploratory study in healthy young males. Hum. Nutr. Metab. 32, 200189 (2023).
doi: 10.1016/j.hnm.2023.200189
Fontana, L., Nehme, J. & Demaria, M. Caloric restriction and cellular senescence. Mech. Ageing Dev. 176, 19–23 (2018).
doi: 10.1016/j.mad.2018.10.005
pubmed: 30395873
Jang, Y. et al. Endurance exercise prevents metabolic distress-induced senescence in the hippocampus. Med. Sci. Sports Exerc. 51, 2012–2024 (2019).
doi: 10.1249/MSS.0000000000002011
pubmed: 30998584
Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 296, 1655–1657 (2002).
doi: 10.1126/science.296.5573.1655
pubmed: 12040186
Akinleye, A., Avvaru, P., Furqan, M., Song, Y. & Liu, D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J. Hematol. Oncol. 6, 88 (2013).
doi: 10.1186/1756-8722-6-88
pubmed: 24261963
pmcid: 3843585
Ortiz, M. A. et al. Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition. Cell Commun. Signal. 19, 67 (2021).
doi: 10.1186/s12964-021-00750-x
pubmed: 34193161
pmcid: 8247114
Anerillas, C. et al. Early SRC activation skews cell fate from apoptosis to senescence. Sci. Adv. 8, eabm0756 (2022).
doi: 10.1126/sciadv.abm0756
pubmed: 35394839
pmcid: 8993123
Roos, C. M. et al. Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell 15, 973–977 (2016).
doi: 10.1111/acel.12458
pubmed: 26864908
pmcid: 5013022
Ogrodnik, M. et al. Cellular senescence drives age-dependent hepatic steatosis. Nat. Commun. 8, 15691 (2017).
doi: 10.1038/ncomms15691
pubmed: 28608850
pmcid: 5474745
Palmer, A. K. et al. Targeting senescent cells alleviates obesity-induced metabolic dysfunction. Aging Cell 18, e12950 (2019).
doi: 10.1111/acel.12950
pubmed: 30907060
pmcid: 6516193
Schafer, M. J. et al. Cellular senescence mediates fibrotic pulmonary disease. Nat. Commun. 8, 14532 (2017).
doi: 10.1038/ncomms14532
pubmed: 28230051
pmcid: 5331226
Islam, M. T. et al. Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age. Aging Cell 22, e13767 (2023).
doi: 10.1111/acel.13767
pubmed: 36637079
pmcid: 9924942
Novais, E. J. et al. Long-term treatment with senolytic drugs dasatinib and quercetin ameliorates age-dependent intervertebral disc degeneration in mice. Nat. Commun. 12, 5213 (2021).
doi: 10.1038/s41467-021-25453-2
pubmed: 34480023
pmcid: 8417260
Zhang, X. et al. Characterization of cellular senescence in aging skeletal muscle. Nat. Aging 2, 601–615 (2022).
doi: 10.1038/s43587-022-00250-8
pubmed: 36147777
pmcid: 9491365
Hochhaus, A. et al. European leukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34, 966–984 (2020).
doi: 10.1038/s41375-020-0776-2
pubmed: 32127639
pmcid: 7214240
Wróbel-Biedrawa, D., Grabowska, K., Galanty, A., Sobolewska, D. & Podolak, I. A flavonoid on the brain: quercetin as a potential therapeutic agent in central nervous system disorders. Life 12, 591 (2022).
doi: 10.3390/life12040591
pubmed: 35455082
pmcid: 9027262
Hickson, L. T. J. et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine 47, 446–456 (2019).
doi: 10.1016/j.ebiom.2019.08.069
pubmed: 31542391
pmcid: 6796530
Justice, J. N. et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine 40, 554–563 (2019).
doi: 10.1016/j.ebiom.2018.12.052
pubmed: 30616998
pmcid: 6412088
Riessland, M. & Orr, M. E. Translating the biology of aging into new therapeutics for Alzheimer’s disease: senolytics. J. Prev. Alzheimers Dis. 10, 633–646 (2023).
pubmed: 37874084
pmcid: 11103249
Garbarino, V. R. et al. Evaluation of exploratory fluid biomarker results from a phase 1 senolytic trial in mild Alzheimer’s disease. Preprint at Res. Sq. https://doi.org/10.21203/rs.3.rs-3994894/v1 (2024).
Yousefzadeh, M. J. et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 36, 18–28 (2018).
doi: 10.1016/j.ebiom.2018.09.015
pubmed: 30279143
pmcid: 6197652
Kumar, R. M. et al. Fisetin in cancer: attributes, developmental aspects, and nanotherapeutics. Pharmaceuticals 16, 196 (2023).
doi: 10.3390/ph16020196
pubmed: 37259344
pmcid: 9961076
Viñas, P., Martínez-Castillo, N., Campillo, N. & Hernández-Córdoba, M. Directly suspended droplet microextraction with in injection-port derivatization coupled to gas chromatography–mass spectrometry for the analysis of polyphenols in herbal infusions, fruits and functional foods. J. Chromatogr. A 1218, 639–646 (2011).
doi: 10.1016/j.chroma.2010.12.026
pubmed: 21185565
Sundarraj, K., Raghunath, A. & Perumal, E. A review on the chemotherapeutic potential of fisetin: in vitro evidences. Biomed. Pharmacother. 97, 928–940 (2018).
doi: 10.1016/j.biopha.2017.10.164
pubmed: 29136771
Zhu, Y. et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-X(L) inhibitors, A1331852 and A1155463. Aging 9, 955–963 (2017).
doi: 10.18632/aging.101202
pubmed: 28273655
pmcid: 5391241
Currais, A. et al. Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function in Alzheimer’s disease transgenic mice. Aging Cell 13, 379–390 (2014).
doi: 10.1111/acel.12185
pubmed: 24341874
He, W. B., Abe, K. & Akaishi, T. Oral administration of fisetin promotes the induction of hippocampal long-term potentiation in vivo. J. Pharmacol. Sci. 136, 42–45 (2018).
doi: 10.1016/j.jphs.2017.12.008
pubmed: 29317180
Zhang, L., Pitcher, L. E., Prahalad, V., Niedernhofer, L. J. & Robbins, P. D. Targeting cellular senescence with senotherapeutics: senolytics and senomorphics. FEBS J. 290, 1362–1383 (2023).
doi: 10.1111/febs.16350
pubmed: 35015337
Mehta, P., Pawar, A., Mahadik, K. & Bothiraja, C. Emerging novel drug delivery strategies for bioactive flavonol fisetin in biomedicine. Biomed. Pharmacother. 106, 1282–1291 (2018).
doi: 10.1016/j.biopha.2018.07.079
pubmed: 30119198
Jornada, D. H. et al. The prodrug approach: a successful tool for improving drug solubility. Molecules 21, 42 (2015).
doi: 10.3390/molecules21010042
pubmed: 26729077
pmcid: 6273601
Herrmann, I. K., Wood, M. J. A. & Fuhrmann, G. Extracellular vesicles as a next-generation drug delivery platform. Nat. Nanotechnol. 16, 748–759 (2021).
doi: 10.1038/s41565-021-00931-2
pubmed: 34211166
Torchilin, V. P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat. Rev. Drug Discov. 13, 813–827 (2014).
doi: 10.1038/nrd4333
pubmed: 25287120
pmcid: 4489143
Hoter, A., El-Sabban, M. E. & Naim, H. Y. The HSP90 family: structure, regulation, function, and implications in health and disease. Int. J. Mol. Sci. 19, 2560 (2018).
doi: 10.3390/ijms19092560
pubmed: 30158430
pmcid: 6164434
Uryu, K. et al. Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies. Am. J. Pathol. 168, 947–961 (2006).
doi: 10.2353/ajpath.2006.050770
pubmed: 16507910
pmcid: 1606542
Tortosa, E. et al. Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein. J. Alzheimers Dis. 17, 319–325 (2009).
doi: 10.3233/JAD-2009-1049
pubmed: 19363271
Fuhrmann-Stroissnigg, H. et al. Identification of HSP90 inhibitors as a novel class of senolytics. Nat. Commun. 8, 422 (2017).
doi: 10.1038/s41467-017-00314-z
pubmed: 28871086
pmcid: 5583353
Pirahanchi, Y., Jessu, R. & Aeddula, N. R. Physiology, sodium potassium pump. StatPearls (2024).
Triana-Martínez, F. et al. Identification and characterization of cardiac glycosides as senolytic compounds. Nat. Commun. 10, 4731 (2019).
doi: 10.1038/s41467-019-12888-x
pubmed: 31636264
pmcid: 6803708
Wang, D. X. et al. GDF11 slows excitatory neuronal senescence and brain ageing by repressing p21. Nat. Commun. 14, 7476 (2023).
doi: 10.1038/s41467-023-43292-1
pubmed: 37978295
pmcid: 10656444
Guerrero, A. et al. Cardiac glycosides are broad-spectrum senolytics. Nat. Metab. 1, 1074–1088 (2019).
doi: 10.1038/s42255-019-0122-z
pubmed: 31799499
pmcid: 6887543
Hardwick, J. M. & Soane, L. Multiple functions of BCL-2 family proteins. Cold Spring Harb. Perspect. Biol. 5, a008722 (2013).
doi: 10.1101/cshperspect.a008722
pubmed: 23378584
pmcid: 3552500
Yosef, R. et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat. Commun. 7, 11190 (2016).
doi: 10.1038/ncomms11190
pubmed: 27048913
pmcid: 4823827
Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421–3428 (2008).
doi: 10.1158/0008-5472.CAN-07-5836
pubmed: 18451170
Chang, J. et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22, 78–83 (2016).
doi: 10.1038/nm.4010
pubmed: 26657143
Schoenwaelder, S. M. et al. Bcl-xL–inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 118, 1663–1674 (2011).
doi: 10.1182/blood-2011-04-347849
pubmed: 21673344
Nakamura, A. et al. Bcl-xL is essential for the survival and function of differentiated neurons in the cortex that control complex behaviors. J. Neurosci. 36, 5448–5461 (2016).
doi: 10.1523/JNEUROSCI.4247-15.2016
pubmed: 27194326
pmcid: 4871982
Koessinger, A. L. et al. Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics. Cell Death Differ. 29, 2089–2104 (2022).
doi: 10.1038/s41418-022-01001-3
pubmed: 35473984
pmcid: 9525582
He, Y. et al. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nat. Commun. 11, 1996 (2020).
doi: 10.1038/s41467-020-15838-0
pubmed: 32332723
pmcid: 7181703
Muñoz-Espín, D. et al. A versatile drug delivery system targeting senescent cells. EMBO Mol. Med. 10, e9355 (2018).
doi: 10.15252/emmm.201809355
pubmed: 30012580
pmcid: 6127887
Agostini, A. et al. Targeted cargo delivery in senescent cells using capped mesoporous silica nanoparticles. Angew. Chem. Int. Ed. Engl. 51, 10556–10560 (2012).
doi: 10.1002/anie.201204663
pubmed: 22996839
González-Gualda, E. et al. Galacto-conjugation of navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity. Aging Cell 19, e13142 (2020).
doi: 10.1111/acel.13142
pubmed: 32233024
pmcid: 7189993
Piechota, M. et al. Is senescence-associated beta-galactosidase a marker of neuronal senescence? Oncotarget 7, 81099–81109 (2016).
doi: 10.18632/oncotarget.12752
pubmed: 27768595
pmcid: 5348379
Hemann, M. T. & Lowe, S. W. The p53–Bcl-2 connection. Cell Death Differ. 13, 1256–1259 (2006).
doi: 10.1038/sj.cdd.4401962
pubmed: 16710363
Kruiswijk, F., Labuschagne, C. F. & Vousden, K. H. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat. Rev. Mol. Cell Biol. 16, 393–405 (2015).
doi: 10.1038/nrm4007
pubmed: 26122615
Baar, M. P. et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell 169, 132–147.e116 (2017).
doi: 10.1016/j.cell.2017.02.031
pubmed: 28340339
pmcid: 5556182
He, Y. et al. Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity. Aging Cell 19, e13117 (2020).
doi: 10.1111/acel.13117
pubmed: 32064756
pmcid: 7059172
Lane, N. et al. A phase 2, randomized, double-blind, placebo-controlled study of senolytic molecule UBX0101 in the treatment of painful knee osteoarthritis. Osteoarthr. Cartil. 29, S52–S53 (2021).
doi: 10.1016/j.joca.2021.02.077
Yoon, Y. S. et al. Senescence and impaired DNA damage responses in alpha-synucleinopathy models. Exp. Mol. Med. 54, 115–128 (2022).
doi: 10.1038/s12276-022-00727-x
pubmed: 35136202
pmcid: 8894476
Mijit, M., Caracciolo, V., Melillo, A., Amicarelli, F. & Giordano, A. Role of p53 in the regulation of cellular senescence. Biomolecules 10, 420 (2020).
doi: 10.3390/biom10030420
pubmed: 32182711
pmcid: 7175209
Wei, S. J. et al. Ketogenic diet induces p53-dependent cellular senescence in multiple organs. Sci. Adv. 10, eado1463 (2024).
doi: 10.1126/sciadv.ado1463
pubmed: 38758782
pmcid: 11100565
West, A. C. & Johnstone, R. W. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124, 30–39 (2014).
doi: 10.1172/JCI69738
pubmed: 24382387
pmcid: 3871231
Crochemore, C., Fernandez-Molina, C., Montagne, B., Salles, A. & Ricchetti, M. CSB promoter downregulation via histone H3 hypoacetylation is an early determinant of replicative senescence. Nat. Commun. 10, 5576 (2019).
doi: 10.1038/s41467-019-13314-y
pubmed: 31811121
pmcid: 6898346
Sen, P. et al. Histone acetyltransferase p300 induces de novo super-enhancers to drive cellular senescence. Mol. Cell 73, 684–698.e688 (2019).
doi: 10.1016/j.molcel.2019.01.021
pubmed: 30773298
pmcid: 6688479
Samaraweera, L., Adomako, A., Rodriguez-Gabin, A. & McDaid, H. M. A novel indication for panobinostat as a senolytic drug in NSCLC and HNSCC. Sci. Rep. 7, 1900 (2017).
doi: 10.1038/s41598-017-01964-1
pubmed: 28507307
pmcid: 5432488
Cheung, K. L., Kim, C. & Zhou, M. M. The functions of BET proteins in gene transcription of biology and diseases. Front. Mol. Biosci. 8, 728777 (2021).
doi: 10.3389/fmolb.2021.728777
pubmed: 34540900
pmcid: 8446420
Hargreaves, D. C., Horng, T. & Medzhitov, R. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 138, 129–145 (2009).
doi: 10.1016/j.cell.2009.05.047
pubmed: 19596240
pmcid: 2828818
Wakita, M. et al. A BET family protein degrader provokes senolysis by targeting NHEJ and autophagy in senescent cells. Nat. Commun. 11, 1935 (2020).
doi: 10.1038/s41467-020-15719-6
pubmed: 32321921
pmcid: 7176673
Lu, J. et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22, 755–763 (2015).
doi: 10.1016/j.chembiol.2015.05.009
pubmed: 26051217
pmcid: 4475452
Yang, M. et al. Transcriptome analysis of human OXR1 depleted cells reveals its role in regulating the p53 signaling pathway. Sci. Rep. 5, 17409 (2015).
doi: 10.1038/srep17409
pubmed: 26616534
pmcid: 4663793
Zhang, X. et al. Oxidation resistance 1 is a novel senolytic target. Aging Cell 17, e12780 (2018).
doi: 10.1111/acel.12780
pubmed: 29766639
pmcid: 6052462
Wang, Y. et al. Discovery of piperlongumine as a potential novel lead for the development of senolytic agents. Aging 8, 2915–2926 (2016).
doi: 10.18632/aging.101100
pubmed: 27913811
pmcid: 5191878
Meiners, F. et al. Computational identification of natural senotherapeutic compounds that mimic dasatinib based on gene expression data. Sci. Rep. 14, 6286 (2024).
doi: 10.1038/s41598-024-55870-4
pubmed: 38491064
pmcid: 10943199
Childs, B. G., Baker, D. J., Kirkland, J. L., Campisi, J. & van Deursen, J. M. Senescence and apoptosis: dueling or complementary cell fates? EMBO Rep. 15, 1139–1153 (2014).
doi: 10.15252/embr.201439245
pubmed: 25312810
pmcid: 4253488
Xu, Q. et al. The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice. Nat. Metab. 3, 1706–1726 (2021).
doi: 10.1038/s42255-021-00491-8
pubmed: 34873338
pmcid: 8688144
Salminen, A. & Kaarniranta, K. Control of p53 and NF-κB signaling by WIP1 and MIF: role in cellular senescence and organismal aging. Cell Signal. 23, 747–752 (2011).
doi: 10.1016/j.cellsig.2010.10.012
pubmed: 20940041
Stagni, V., Ferri, A., Cirotti, C. & Barilà, D. ATM kinase-dependent regulation of autophagy: a key player in senescence? Front. Cell Dev. Biol. 8, 599048 (2020).
doi: 10.3389/fcell.2020.599048
pubmed: 33490066
Hewitt, G. & Korolchuk, V. I. Repair, reuse, recycle: the expanding role of autophagy in genome maintenance. Trends Cell Biol. 27, 340–351 (2017).
doi: 10.1016/j.tcb.2016.11.011
pubmed: 28011061
Zhao, J. et al. ATM is a key driver of NF-κB-dependent DNA-damage-induced senescence, stem cell dysfunction and aging. Aging 12, 4688–4710 (2020).
doi: 10.18632/aging.102863
pubmed: 32201398
pmcid: 7138542
Zou, Z., Tao, T., Li, H. & Zhu, X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 10, 31 (2020).
doi: 10.1186/s13578-020-00396-1
pubmed: 32175074
pmcid: 7063815
Neufeld, T. P. TOR-dependent control of autophagy: biting the hand that feeds. Curr. Opin. Cell Biol. 22, 157–168 (2010).
doi: 10.1016/j.ceb.2009.11.005
pubmed: 20006481
Lamming, D. W., Ye, L., Sabatini, D. M. & Baur, J. A. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J. Clin. Invest. 123, 980–989 (2013).
doi: 10.1172/JCI64099
pubmed: 23454761
pmcid: 3582126
Harrison, D. E. et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392–395 (2009).
doi: 10.1038/nature08221
pubmed: 19587680
pmcid: 2786175
Wang, R. et al. Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism. Aging Cell 16, 564–574 (2017).
doi: 10.1111/acel.12587
pubmed: 28371119
pmcid: 5418203
Demaria, M. et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev. Cell 31, 722–733 (2014).
doi: 10.1016/j.devcel.2014.11.012
pubmed: 25499914
pmcid: 4349629
Li, J., Kim, S. G. & Blenis, J. Rapamycin: one drug, many effects. Cell Metab. 19, 373–379 (2014).
doi: 10.1016/j.cmet.2014.01.001
pubmed: 24508508
pmcid: 3972801
Fielder, E. et al. Anti-inflammatory treatment rescues memory deficits during aging in Nfkb1
doi: 10.1111/acel.13188
pubmed: 32915495
pmcid: 7576267
Israël, A. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb. Perspect. Biol. 2, a000158 (2010).
doi: 10.1101/cshperspect.a000158
pubmed: 20300203
pmcid: 2829958
Tilstra, J. S. et al. NF-κB inhibition delays DNA damage-induced senescence and aging in mice. J. Clin. Invest. 122, 2601–2612 (2012).
doi: 10.1172/JCI45785
pubmed: 22706308
pmcid: 3386805
Zhang, L. et al. Novel small molecule inhibition of IKK/NF-κB activation reduces markers of senescence and improves healthspan in mouse models of aging. Aging Cell 20, e13486 (2021).
doi: 10.1111/acel.13486
pubmed: 34734460
pmcid: 8672781
Zhao, J. et al. Development of novel NEMO-binding domain mimetics for inhibiting IKK/NF-κB activation. PLoS Biol. 16, e2004663 (2018).
doi: 10.1371/journal.pbio.2004663
pubmed: 29889904
pmcid: 6013238
Englund, D. A. et al. Senotherapeutic drug treatment ameliorates chemotherapy-induced cachexia. JCI Insight 9, e169512 (2024).
doi: 10.1172/jci.insight.169512
pubmed: 38051584
pmcid: 10906225
Saha, R. N., Jana, M. & Pahan, K. MAPK p38 regulates transcriptional activity of NF-kappaB in primary human astrocytes via acetylation of p65. J. Immunol. 179, 7101–7109 (2007).
doi: 10.4049/jimmunol.179.10.7101
pubmed: 17982102
Khalil, R., Diab-Assaf, M. & Lemaitre, J. M. Emerging therapeutic approaches to target the dark side of senescent cells: new hopes to treat aging as a disease and to delay age-related pathologies. Cells 12, 915 (2023).
doi: 10.3390/cells12060915
pubmed: 36980256
pmcid: 10047596
Alimbetov, D. et al. Suppression of the senescence-associated secretory phenotype (SASP) in human fibroblasts using small molecule inhibitors of p38 MAP kinase and MK2. Biogerontology 17, 305–315 (2016).
doi: 10.1007/s10522-015-9610-z
pubmed: 26400758
Salotti, J. & Johnson, P. F. Regulation of senescence and the SASP by the transcription factor C/EBPbeta. Exp. Gerontol. 128, 110752 (2019).
doi: 10.1016/j.exger.2019.110752
pubmed: 31648009
Xu, M. et al. JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. Proc. Natl Acad. Sci. USA 112, E6301–E6310 (2015).
doi: 10.1073/pnas.1515386112
pubmed: 26578790
pmcid: 4655580
Pasqualetti, P. et al. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease. Aging Clin. Exp. Res. 21, 102–110 (2009).
doi: 10.1007/BF03325217
pubmed: 19448381
Tabet, N. & Feldmand, H. Ibuprofen for Alzheimer’s disease. Cochrane Database Syst. Rev. 2, CD004031 (2003).
Marin, I., Serrano, M. & Pietrocola, F. Recent insights into the crosstalk between senescent cells and CD8 T lymphocytes. NPJ Aging 9, 8 (2023).
doi: 10.1038/s41514-023-00105-5
pubmed: 37015935
pmcid: 10073090
Arora, S. et al. Invariant natural killer T cells coordinate removal of senescent cells. Med 2, 938–950 (2021).
doi: 10.1016/j.medj.2021.04.014
pubmed: 34617070
Brelstaff, J., Tolkovsky, A. M., Ghetti, B., Goedert, M. & Spillantini, M. G. Living neurons with tau filaments aberrantly expose phosphatidylserine and are phagocytosed by microglia. Cell Rep. 24, 1939–1948.e1934 (2018).
doi: 10.1016/j.celrep.2018.07.072
pubmed: 30134156
pmcid: 6161320
Giannoula, Y., Kroemer, G. & Pietrocola, F. Cellular senescence and the host immune system in aging and age-related disorders. Biomed. J. 46, 100581 (2023).
doi: 10.1016/j.bj.2023.02.001
pubmed: 36746349
pmcid: 10210012
Lee, S. et al. A guide to senolytic intervention in neurodegenerative disease. Mech. Ageing Dev. 200, 111585 (2021).
doi: 10.1016/j.mad.2021.111585
pubmed: 34627838
pmcid: 8627445
Amor, C. et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 583, 127–132 (2020).
doi: 10.1038/s41586-020-2403-9
pubmed: 32555459
pmcid: 7583560
Kim, K. M. et al. Identification of senescent cell surface targetable protein DPP4. Genes Dev. 31, 1529–1534 (2017).
doi: 10.1101/gad.302570.117
pubmed: 28877934
pmcid: 5630018
Suda, M. et al. Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. Nat. Aging 1, 1117–1126 (2021).
doi: 10.1038/s43587-021-00151-2
pubmed: 37117524
Lear, T. B. & Finkel, T. Senolytic vaccination: a new mandate for cardiovascular health? J. Cardiovasc. Aging 2, 17 (2022).
pubmed: 36819765
pmcid: 9937554
Saade, M., Araujo de Souza, G., Scavone, C. & Kinoshita, P. F. The role of GPNMB in inflammation. Front. Immunol. 12, 674739 (2021).
doi: 10.3389/fimmu.2021.674739
pubmed: 34054862
pmcid: 8149902
Huang, J. et al. Emerging role of dipeptidyl peptidase-4 in autoimmune disease. Front. Immunol. 13, 830863 (2022).
doi: 10.3389/fimmu.2022.830863
pubmed: 35309368
pmcid: 8931313
Hamada, M. et al. Urokinase-type plasminogen activator receptor (uPAR) in inflammation and disease: a unique inflammatory pathway activator. Biomedicines 12, 1167 (2024).
doi: 10.3390/biomedicines12061167
pubmed: 38927374
pmcid: 11201033
Marchetti, L. & Engelhardt, B. Immune cell trafficking across the blood-brain barrier in the absence and presence of neuroinflammation. Vasc. Biol. 2, H1–H18 (2020).
doi: 10.1530/VB-19-0033
pubmed: 32923970
pmcid: 7439848
Chaib, S., Tchkonia, T. & Kirkland, J. L. Cellular senescence and senolytics: the path to the clinic. Nat. Med. 28, 1556–1568 (2022).
doi: 10.1038/s41591-022-01923-y
pubmed: 35953721
pmcid: 9599677
Kaur, P. et al. Combining stem cell rejuvenation and senescence targeting to synergistically extend lifespan. Aging 14, 8270–8291 (2022).
pubmed: 36287172
pmcid: 9648810
Ziegler, D. V., Martin, N. & Bernard, D. Cellular senescence links mitochondria–ER contacts and aging. Commun. Biol. 4, 1323 (2021).
doi: 10.1038/s42003-021-02840-5
pubmed: 34819602
pmcid: 8613202
Kim, S. et al. Supramolecular senolytics via intracellular oligomerization of peptides in response to elevated reactive oxygen species levels in aging cells. J. Am. Chem. Soc. 145, 21991–22008 (2023).
doi: 10.1021/jacs.3c06898
pubmed: 37664981
Liao, K. M. et al. Senomorphic effect of diphenyleneiodonium through AMPK/MFF/DRP1 mediated mitochondrial fission. Biomed. Pharmacother. 162, 114616 (2023).
doi: 10.1016/j.biopha.2023.114616
pubmed: 37004322
Aguado, J. et al. Inhibition of the cGAS-STING pathway ameliorates the premature senescence hallmarks of ataxia-telangiectasia brain organoids. Aging Cell 20, e13468 (2021).
doi: 10.1111/acel.13468
pubmed: 34459078
pmcid: 8441292
Gulen, M. F. et al. cGAS–STING drives ageing-related inflammation and neurodegeneration. Nature 620, 374–380 (2023).
doi: 10.1038/s41586-023-06373-1
pubmed: 37532932
pmcid: 10412454
Vijay Kumar, M. J., Morales, R. & Tsvetkov, A. S. G-quadruplexes and associated proteins in aging and Alzheimer’s disease. Front. Aging 4, 1164057 (2023).
doi: 10.3389/fragi.2023.1164057
pubmed: 37323535
pmcid: 10267416
Saunderson, E. A. et al. Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors. Nat. Commun. 8, 1450 (2017).
doi: 10.1038/s41467-017-01078-2
pubmed: 29133799
pmcid: 5684409
De Cecco, M. et al. L1 drives IFN in senescent cells and promotes age-associated inflammation. Nature 566, 73–78 (2019).
doi: 10.1038/s41586-018-0784-9
pubmed: 30728521
pmcid: 6519963
Mohs, R. C. & Greig, N. H. Drug discovery and development: role of basic biological research. Alzheimers Dement. 3, 651–657 (2017).
Kurauchi, Y., Noma, K., Hisatsune, A., Seki, T. & Katsuki, H. Na+, K+-ATPase inhibition induces neuronal cell death in rat hippocampal slice cultures: association with GLAST and glial cell abnormalities. J. Pharmacol. Sci. 138, 167–175 (2018).
doi: 10.1016/j.jphs.2018.09.004
pubmed: 30322800
Robinson, E. J. et al. Survival of midbrain dopamine neurons depends on the Bcl2 factor Mcl1. Cell Death Discov. 4, 107 (2018).
doi: 10.1038/s41420-018-0125-7
pubmed: 30479840
pmcid: 6249233
Kassed, C. A., Willing, A. E., Garbuzova-Davis, S., Sanberg, P. R. & Pennypacker, K. R. Lack of NF-kappaB p50 exacerbates degeneration of hippocampal neurons after chemical exposure and impairs learning. Exp. Neurol. 176, 277–288 (2002).
doi: 10.1006/exnr.2002.7967
pubmed: 12359170
Childs, B. G. et al. Senescent cells: an emerging target for diseases of ageing. Nat. Rev. Drug Discov. 16, 718–735 (2017).
doi: 10.1038/nrd.2017.116
pubmed: 28729727
pmcid: 5942225
Sakamoto, K. M. et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl Acad. Sci. USA 98, 8554–8559 (2001).
doi: 10.1073/pnas.141230798
pubmed: 11438690
pmcid: 37474
Lopez-Seijas, J. et al. Development of new non-viral systems for genetic modification of senescent cells. Mol. Ther. Nucleic Acids 32, 302–317 (2023).
doi: 10.1016/j.omtn.2023.03.010
pubmed: 37096164
pmcid: 10122050
Marchi, N. et al. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Med. 2, 37 (2004).
doi: 10.1186/1741-7015-2-37
pubmed: 15473912
pmcid: 524356
Friden, P. M. et al. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc. Natl Acad. Sci. USA 88, 4771–4775 (1991).
doi: 10.1073/pnas.88.11.4771
pubmed: 2052557
pmcid: 51748
Pornnoppadol, G. et al. Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs. Cell Chem. Biol. 31, 361–372.e368 (2024).
doi: 10.1016/j.chembiol.2023.09.008
pubmed: 37890480
Pardridge, W. M. Drug transport across the blood–brain barrier. J. Cereb. Blood Flow Metab. 32, 1959–1972 (2012).
doi: 10.1038/jcbfm.2012.126
pubmed: 22929442
pmcid: 3494002
Pardridge, W. M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2, 3–14 (2005).
doi: 10.1602/neurorx.2.1.3
pubmed: 15717053
pmcid: 539316
Alavijeh, M. S., Chishty, M., Qaiser, M. Z. & Palmer, A. M. Drug metabolism and pharmacokinetics, the blood–brain barrier, and central nervous system drug discovery. NeuroRx 2, 554–571 (2005).
doi: 10.1602/neurorx.2.4.554
pubmed: 16489365
pmcid: 1201315
Bryant, A. G. et al. Cerebrovascular senescence is associated with tau pathology in Alzheimer’s disease. Front. Neurol. 11, 575953 (2020).
doi: 10.3389/fneur.2020.575953
pubmed: 33041998
pmcid: 7525127
Yabluchanskiy, A. et al. Pharmacological or genetic depletion of senescent astrocytes prevents whole brain irradiation-induced impairment of neurovascular coupling responses protecting cognitive function in mice. Geroscience 42, 409–428 (2020).
doi: 10.1007/s11357-020-00154-8
pubmed: 31960269
pmcid: 7205933
Ng, P. Y., Zhang, C., Li, H. & Baker, D. J. Senescence targeting methods impact Alzheimer’s disease features in 3xTg mice. J. Alzheimers Dis. 97, 1751–1763 (2024).
doi: 10.3233/JAD-230465
pubmed: 38306030
pmcid: 10939718
Fletcher-Sananikone, E. et al. Elimination of radiation-induced senescence in the brain tumor microenvironment attenuates glioblastoma recurrence. Cancer Res. 81, 5935–5947 (2021).
doi: 10.1158/0008-5472.CAN-21-0752
pubmed: 34580063
pmcid: 9724593
Karpel-Massler, G. et al. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL. Nat. Commun. 8, 1067 (2017).
doi: 10.1038/s41467-017-00984-9
pubmed: 29057925
pmcid: 5651864
Yousefzadeh, M. J. et al. An aged immune system drives senescence and ageing of solid organs. Nature 594, 100–105 (2021).
doi: 10.1038/s41586-021-03547-7
pubmed: 33981041
pmcid: 8684299
Crespo-Garcia, S. et al. Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results. Nat. Med. 30, 443–454 (2024).
doi: 10.1038/s41591-024-02802-4
pubmed: 38321220
West, S., Nolan, S. J. & Newton, R. Surgery for epilepsy: a systematic review of current evidence. Epileptic Disord. 18, 113–121 (2016).
doi: 10.1684/epd.2016.0825
pubmed: 27193634
Herdy, J. R. et al. Increased post-mitotic senescence in aged human neurons is a pathological feature of Alzheimer’s disease. Cell Stem Cell 29, 1637–1652.e1636 (2022).
doi: 10.1016/j.stem.2022.11.010
pubmed: 36459967
pmcid: 10093780
Wu, J. W. et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci. 19, 1085–1092 (2016).
doi: 10.1038/nn.4328
pubmed: 27322420
pmcid: 4961585
Franzmeier, N. et al. Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nat. Commun. 13, 1362 (2022).
doi: 10.1038/s41467-022-28896-3
pubmed: 35292638
pmcid: 8924216
Neher, J. J. et al. Inhibition of microglial phagocytosis is sufficient to prevent inflammatory neuronal death. J. Immunol. 186, 4973–4983 (2011).
doi: 10.4049/jimmunol.1003600
pubmed: 21402900
Puigdellivol, M. et al. The microglial P2Y
doi: 10.1016/j.celrep.2021.110148
pubmed: 34965424
pmcid: 8733854
Milde, S. et al. Inflammatory neuronal loss in the substantia nigra induced by systemic lipopolysaccharide is prevented by knockout of the P2Y
doi: 10.1186/s12974-021-02280-2
Dundee, J. M., Puigdellivol, M., Butler, R., Cockram, T. O. J. & Brown, G. C. P2Y
doi: 10.1111/acel.13761
pubmed: 36565471
Maynard, J. & Hart, P. The opportunities and use of imaging to measure target engagement. SLAS Discov. 25, 127–136 (2020).
doi: 10.1177/2472555219897270
pubmed: 31885303
Matthews, P. M., Rabiner, E. A., Passchier, J. & Gunn, R. N. Positron emission tomography molecular imaging for drug development. Br. J. Clin. Pharmacol. 73, 175–186 (2012).
doi: 10.1111/j.1365-2125.2011.04085.x
pubmed: 21838787
pmcid: 3269576
Brickute, D. et al. Design, synthesis, and evaluation of a novel PET imaging agent targeting lipofuscin in senescent cells. RSC Adv. 12, 26372–26381 (2022).
doi: 10.1039/D2RA04535D
pubmed: 36275107
pmcid: 9475417
Krueger, M. A. et al. Abstract 1146: [
doi: 10.1158/1538-7445.AM2019-1146
Benavides, S. H., Monserrat, A. J., Farina, S. & Porta, E. A. Sequential histochemical studies of neuronal lipofuscin in human cerebral cortex from the first to the ninth decade of life. Arch. Gerontol. Geriatr. 34, 219–231 (2002).
doi: 10.1016/S0167-4943(01)00223-0
pubmed: 14764325
Rossi, M. & Abdelmohsen, K. The emergence of senescent surface biomarkers as senotherapeutic targets. Cells 10, 1740 (2021).
doi: 10.3390/cells10071740
pubmed: 34359910
pmcid: 8305747
Poblocka, M. et al. Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker. Sci. Rep. 11, 20358 (2021).
doi: 10.1038/s41598-021-99852-2
pubmed: 34645909
pmcid: 8514501
Fu, R., Carroll, L., Yahioglu, G., Aboagye, E. O. & Miller, P. W. Antibody fragment and affibody immunopet imaging agents: radiolabelling strategies and applications. ChemMedChem 13, 2466–2478 (2018).
doi: 10.1002/cmdc.201800624
pubmed: 30246488
pmcid: 6587488
Wiley, C. D. et al. Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype. Sci. Rep. 8, 2410 (2018).
doi: 10.1038/s41598-018-20000-4
pubmed: 29402901
pmcid: 5799282
Liu, Y. et al. Expression of p16
doi: 10.1111/j.1474-9726.2009.00489.x
pubmed: 19485966
Justice, J. N. et al. Caloric restriction intervention alters specific circulating biomarkers of the senescence-associated secretome in middle-aged and older adults with obesity and prediabetes in an 18-week randomized controlled trial. J. Gerontol. A Biol. Sci. Med. Sci. 79, glad214 (2024).
doi: 10.1093/gerona/glad214
pubmed: 37738560
Mitin, N. et al. A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer. NPJ Breast Cancer 8, 103 (2022).
doi: 10.1038/s41523-022-00473-3
pubmed: 36075910
pmcid: 9458644
Schafer, M. J. et al. The senescence-associated secretome as an indicator of age and medical risk. JCI insight 5, e133668 (2020).
doi: 10.1172/jci.insight.133668
pubmed: 32554926
pmcid: 7406245
Basisty, N. et al. A proteomic atlas of senescence-associated secretomes for aging biomarker development. PLoS Biol. 18, e3000599 (2020).
doi: 10.1371/journal.pbio.3000599
pubmed: 31945054
pmcid: 6964821
Basisty, N., Kale, A., Patel, S., Campsi, J. & Schilling, B. The power of proteomics to monitor senescence-associated secretory phenotypes and beyond: toward clinical applications. Expert Rev. Proteomics 17, 297–308 (2020).
doi: 10.1080/14789450.2020.1766976
pubmed: 32425074
pmcid: 7416420
Gurkar, A. U. et al. Spatial mapping of cellular senescence: emerging challenges and opportunities. Nat. Aging 3, 776–790 (2023).
doi: 10.1038/s43587-023-00446-6
pubmed: 37400722
pmcid: 10505496
Vatansever, S. et al. Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: state-of-the-arts and future directions. Med. Res. Rev. 41, 1427–1473 (2021).
doi: 10.1002/med.21764
pubmed: 33295676
Vamathevan, J. et al. Applications of machine learning in drug discovery and development. Nat. Rev. Drug Discov. 18, 463–477 (2019).
doi: 10.1038/s41573-019-0024-5
pubmed: 30976107
pmcid: 6552674
DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20–33 (2016).
doi: 10.1016/j.jhealeco.2016.01.012
pubmed: 26928437
Waring, M. J. et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 14, 475–486 (2015).
doi: 10.1038/nrd4609
pubmed: 26091267
Hughes, B. K., Wallis, R. & Bishop, C. L. Yearning for machine learning: applications for the classification and characterisation of senescence. Cell Tissue Res. 394, 1–16 (2023).
doi: 10.1007/s00441-023-03768-4
pubmed: 37016180
pmcid: 10558380
Ito, T. K. et al. A crucial role for CDC42 in senescence-associated inflammation and atherosclerosis. PLoS ONE 9, e102186 (2014).
doi: 10.1371/journal.pone.0102186
pubmed: 25057989
pmcid: 4109913
Kerber, R. A., O’Brien, E. & Cawthon, R. M. Gene expression profiles associated with aging and mortality in humans. Aging Cell 8, 239–250 (2009).
doi: 10.1111/j.1474-9726.2009.00467.x
pubmed: 19245677
Khadirnaikar, S., Chatterjee, A. & Shukla, S. Identification and characterization of senescence phenotype in lung adenocarcinoma with high drug sensitivity. Am. J. Pathol. 191, 1966–1973 (2021).
doi: 10.1016/j.ajpath.2021.07.005
pubmed: 34358516
Kusumoto, D. et al. Anti-senescent drug screening by deep learning-based morphology senescence scoring. Nat. Commun. 12, 257 (2021).
doi: 10.1038/s41467-020-20213-0
pubmed: 33431893
pmcid: 7801636
Pun, F. W. et al. A comprehensive AI-driven analysis of large-scale omic datasets reveals novel dual-purpose targets for the treatment of cancer and aging. Aging Cell 22, e14017 (2023).
doi: 10.1111/acel.14017
pubmed: 37888486
pmcid: 10726874
Smer-Barreto, V. et al. Discovery of senolytics using machine learning. Nat. Commun. 14, 3445 (2023).
doi: 10.1038/s41467-023-39120-1
pubmed: 37301862
pmcid: 10257182
Hopkins, A. L. & Groom, C. R. The druggable genome. Nat. Rev. Drug Discov. 1, 727–730 (2002).
doi: 10.1038/nrd892
pubmed: 12209152
Hughes, J. P., Rees, S., Kalindjian, S. B. & Philpott, K. L. Principles of early drug discovery. Br. J. Pharmacol. 162, 1239–1249 (2011).
doi: 10.1111/j.1476-5381.2010.01127.x
pubmed: 21091654
pmcid: 3058157
Batool, M., Ahmad, B. & Choi, S. A structure-based drug discovery paradigm. Int. J. Mol. Sci. 20, 2783 (2019).
doi: 10.3390/ijms20112783
pubmed: 31174387
pmcid: 6601033
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).
doi: 10.1038/s41586-021-03819-2
pubmed: 34265844
pmcid: 8371605
Avelar, R. A. et al. A multidimensional systems biology analysis of cellular senescence in aging and disease. Genome Biol. 21, 91 (2020).
doi: 10.1186/s13059-020-01990-9
pubmed: 32264951
pmcid: 7333371
Hasin, Y., Seldin, M. & Lusis, A. Multi-omics approaches to disease. Genome Biol. 18, 83 (2017).
doi: 10.1186/s13059-017-1215-1
pubmed: 28476144
pmcid: 5418815
No place like home The Live-in Care Hub https://www.liveincarehub.co.uk/no-place-like-home-report/ (2021).
Mehegan, L. & Rainville, C. 2021 AARP survey on the perceptions related to a dementia diagnosis: adults age 40+. aarp.org https://www.aarp.org/content/dam/aarp/research/surveys_statistics/health/2021/dementia-diagnosis-perceptions.doi.10.26419-2Fres.00471.001.pdf (AARP Research, 2021).
Watson, R., Sanson-Fisher, R., Bryant, J. & Mansfield, E. Dementia is the second most feared condition among Australian health service consumers: results of a cross-sectional survey. BMC Public Health 23, 876 (2023).
doi: 10.1186/s12889-023-15772-y
pubmed: 37173717
pmcid: 10176813
Turnquist, C. et al. p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration. Cell Death Differ. 23, 1515–1528 (2016).
doi: 10.1038/cdd.2016.37
pubmed: 27104929
pmcid: 5072428
Choi, I. et al. Autophagy enables microglia to engage amyloid plaques and prevents microglial senescence. Nat. Cell Biol. 25, 963–974 (2023).
doi: 10.1038/s41556-023-01158-0
pubmed: 37231161
pmcid: 10950302
Wu, D., Sun, J. K. & Chow, K. H. Neuronal cell cycle reentry events in the aging brain are more prevalent in neurodegeneration and lead to cellular senescence. PLoS Biol. 22, e3002559 (2024).
doi: 10.1371/journal.pbio.3002559
pubmed: 38652714
pmcid: 11037540
Bitto, A. et al. Stress-induced senescence in human and rodent astrocytes. Exp. Cell Res. 316, 2961–2968 (2010).
doi: 10.1016/j.yexcr.2010.06.021
pubmed: 20620137
Ogrodnik, M. et al. Whole-body senescent cell clearance alleviates age-related brain inflammation and cognitive impairment in mice. Aging Cell 20, e13296 (2021).
doi: 10.1111/acel.13296
pubmed: 33470505
pmcid: 7884042
Jin, W. N. et al. Neuroblast senescence in the aged brain augments natural killer cell cytotoxicity leading to impaired neurogenesis and cognition. Nat. Neurosci. 24, 61–73 (2021).
doi: 10.1038/s41593-020-00745-w
pubmed: 33257875
Das, M. M. & Svendsen, C. N. Astrocytes show reduced support of motor neurons with aging that is accelerated in a rodent model of ALS. Neurobiol. Aging 36, 1130–1139 (2015).
doi: 10.1016/j.neurobiolaging.2014.09.020
pubmed: 25443290
Vazquez-Villasenor, I. et al. Expression of p16 and p21 in the frontal association cortex of ALS/MND brains suggests neuronal cell cycle dysregulation and astrocyte senescence in early stages of the disease. Neuropathol. Appl. Neurobiol. 46, 171–185 (2020).
doi: 10.1111/nan.12559
pubmed: 31077599
Trias, E. et al. Emergence of microglia bearing senescence markers during paralysis progression in a rat model of inherited ALS. Front. Aging Neurosci. 11, 42 (2019).
doi: 10.3389/fnagi.2019.00042
pubmed: 30873018
pmcid: 6403180
Torres, P. et al. A motor neuron disease mouse model reveals a non-canonical profile of senescence biomarkers. Dis. Model. Mech. 15, dmm049059 (2022).
doi: 10.1242/dmm.049059
pubmed: 35916061
pmcid: 9459393
Borgonetti, V. & Galeotti, N. Rosmarinic acid reduces microglia senescence: a novel therapeutic approach for the management of neuropathic pain symptoms. Biomedicines 10, 1468 (2022).
doi: 10.3390/biomedicines10071468
pubmed: 35884774
pmcid: 9312967
Lim, S. et al. Senolytic therapy for cerebral ischemia-reperfusion injury. Int. J. Mol. Sci. 22, 11967 (2021).
doi: 10.3390/ijms222111967
pubmed: 34769397
pmcid: 8584561
Lu, K. J. et al. Ability of local clearance of senescent cells in ipsilateral hemisphere to mitigate acute ischemic brain injury in mice. Int. J. Biol. Sci. 19, 2835–2847 (2023).
doi: 10.7150/ijbs.84060
pubmed: 37324944
pmcid: 10266088
Torres-Querol, C. et al. Acute ischemic stroke triggers a cellular senescence-associated secretory phenotype. Sci. Rep. 11, 15752 (2021).
doi: 10.1038/s41598-021-95344-5
pubmed: 34344977
pmcid: 8333348
Tominaga, T., Shimada, R., Okada, Y., Kawamata, T. & Kibayashi, K. Senescence-associated-beta-galactosidase staining following traumatic brain injury in the mouse cerebrum. PLoS ONE 14, e0213673 (2019).
doi: 10.1371/journal.pone.0213673
pubmed: 30856215
pmcid: 6411151
Schwab, N., Grenier, K. & Hazrati, L. N. DNA repair deficiency and senescence in concussed professional athletes involved in contact sports. Acta Neuropathol. Commun. 7, 182 (2019).
doi: 10.1186/s40478-019-0822-3
pubmed: 31727161
pmcid: 6857343
Ritzel, R. M. et al. Old age increases microglial senescence, exacerbates secondary neuroinflammation, and worsens neurological outcomes after acute traumatic brain injury in mice. Neurobiol. Aging 77, 194–206 (2019).
doi: 10.1016/j.neurobiolaging.2019.02.010
pubmed: 30904769
pmcid: 6486858
Skowronska-Krawczyk, D. et al. P16
doi: 10.1016/j.molcel.2015.07.027
pubmed: 26365380
pmcid: 4648709
Yang, L. et al. SARS-CoV-2 infection causes dopaminergic neuron senescence. Cell Stem Cell 31, 196–211.e196 (2024).
doi: 10.1016/j.stem.2023.12.012
pubmed: 38237586
pmcid: 10843182
Salam, R. et al. Cellular senescence in malignant cells promotes tumor progression in mouse and patient glioblastoma. Nat. Commun. 14, 441 (2023).
doi: 10.1038/s41467-023-36124-9
pubmed: 36707509
pmcid: 9883514
Beltzig, L. et al. Senescence is the main trait induced by temozolomide in glioblastoma cells. Cancers 14, 2233 (2022).
doi: 10.3390/cancers14092233
pubmed: 35565362
pmcid: 9102829
Nicaise, A. M. et al. Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis. Proc. Natl Acad. Sci. USA 116, 9030–9039 (2019).
doi: 10.1073/pnas.1818348116
pubmed: 30910981
pmcid: 6500153
Porkka, K. et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 112, 1005–1012 (2008).
doi: 10.1182/blood-2008-02-140665
pubmed: 18477770
Costa, L. G., Garrick, J. M., Roquè, P. J. & Pellacani, C. Mechanisms of neuroprotection by quercetin: counteracting oxidative stress and more. Oxid. Med. Cell. Longev. 2016, 2986796 (2016).
doi: 10.1155/2016/2986796
pubmed: 26904161
pmcid: 4745323
Rivera, F., Urbanavicius, J., Gervaz, E., Morquio, A. & Dajas, F. Some aspects of the in vivo neuroprotective capacity of flavonoids: bioavailability and structure-activity relationship. Neurotox. Res. 6, 543–553 (2004).
doi: 10.1007/BF03033450
pubmed: 15639786
Wang, C. et al. Combined use of dasatinib and quercetin alleviates overtraining-induced deficits in learning and memory through eliminating senescent cells and reducing apoptotic cells in rat hippocampus. Behav. Brain Res. 440, 114260 (2023).
doi: 10.1016/j.bbr.2022.114260
pubmed: 36535433
Krzystyniak, A. et al. Combination of dasatinib and quercetin improves cognitive abilities in aged male Wistar rats, alleviates inflammation and changes hippocampal synaptic plasticity and histone H3 methylation profile. Aging 14, 572–595 (2022).
doi: 10.18632/aging.203835
pubmed: 35042834
pmcid: 8833137
Brandt, C. et al. The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy. Neuropharmacology 140, 107–120 (2018).
doi: 10.1016/j.neuropharm.2018.08.002
pubmed: 30081001
Kolosova, N. G. et al. Rapamycin suppresses brain aging in senescence-accelerated OXYS rats. Aging 5, 474–484 (2013).
doi: 10.18632/aging.100573
pubmed: 23817674
pmcid: 3824413
Van Skike, C. E. et al. mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging. Aging Cell 19, e13057 (2020).
doi: 10.1111/acel.13057
pubmed: 31693798
Hay, D. G. et al. Progressive decrease in chaperone protein levels in a mouse model of Huntington’s disease and induction of stress proteins as a therapeutic approach. Hum. Mol. Genet. 13, 1389–1405 (2004).
doi: 10.1093/hmg/ddh144
pubmed: 15115766
Putcha, P. et al. Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. J. Pharmacol. Exp. Ther. 332, 849–857 (2010).
doi: 10.1124/jpet.109.158436
pubmed: 19934398
pmcid: 2835433
O’Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaaa0984 (2017).
doi: 10.1126/scitranslmed.aaa0984
pubmed: 28724573
pmcid: 5762203
Iwasaki, A. Immune regulation of antibody access to neuronal tissues. Trends Mol. Med. 23, 227–245 (2017).
doi: 10.1016/j.molmed.2017.01.004
pubmed: 28185790
pmcid: 5626569
Yang, X. S. et al. Ouabain suppresses the growth and migration abilities of glioma U-87MG cells through inhibiting the Akt/mTOR signaling pathway and downregulating the expression of HIF-1α. Mol. Med. Rep. 17, 5595–5600 (2018).
pubmed: 29436645
pmcid: 5865999
Lan, Y. L. et al. Bufalin inhibits glioblastoma growth by promoting proteasomal degradation of the Na
doi: 10.1016/j.biopha.2018.04.030
pubmed: 29653366
Storstein, L., Nore, A. K. & Sjaastad, O. Studies on digitalis. 23. Blood-brain barrier of digitoxin in humans. Clin. Cardiol. 2, 146–150 (1979).
doi: 10.1002/clc.4960020211
pubmed: 262570
Tsyvunin, V., Shtrygol, S. & Shtrygol, D. Digoxin enhances the effect of antiepileptic drugs with different mechanism of action in the pentylenetetrazole-induced seizures in mice. Epilepsy Res. 167, 106465 (2020).
doi: 10.1016/j.eplepsyres.2020.106465
pubmed: 33010621
Dvela-Levitt, M., Ami, H. C., Rosen, H., Shohami, E. & Lichtstein, D. Ouabain improves functional recovery following traumatic brain injury. J. Neurotrauma 31, 1942–1947 (2014).
doi: 10.1089/neu.2014.3544
pubmed: 25007121
pmcid: 4238276
Erdogan, M. A., Kirazlar, M., Yigitturk, G. & Erbas, O. Digoxin exhibits neuroprotective properties in a rat model of dementia. Neurochem. Res. 47, 1290–1298 (2022).
doi: 10.1007/s11064-022-03528-w
pubmed: 35064518
Hassan, J. W. & Bhatwadekar, A. D. Senolytics in the treatment of diabetic retinopathy. Front. Pharmacol. 13, 896907 (2022).
doi: 10.3389/fphar.2022.896907
pubmed: 36091769
pmcid: 9462063
Yamaguchi, R. & Perkins, G. Finding a panacea among combination cancer therapies. Cancer Res. 72, 18–23 (2012).
doi: 10.1158/0008-5472.CAN-11-3091
pubmed: 22052464
Moujalled, D. et al. BH3 mimetic drugs cooperate with temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells. Cell Death Differ. 29, 1335–1348 (2022).
doi: 10.1038/s41418-022-00977-2
pubmed: 35332309
pmcid: 9287558
Aguado, J. et al. Senolytic therapy alleviates physiological human brain aging and COVID-19 neuropathology. Nat. Aging 3, 1561–1575 (2023).
doi: 10.1038/s43587-023-00519-6
pubmed: 37957361
pmcid: 10724067
Gulej, R. et al. Elimination of senescent cells by treatment with navitoclax/ABT263 reverses whole brain irradiation-induced blood-brain barrier disruption in the mouse brain. Geroscience 45, 2983–3002 (2023).
doi: 10.1007/s11357-023-00870-x
pubmed: 37642933
pmcid: 10643778
Fatt, M. P. et al. Restoration of hippocampal neural precursor function by ablation of senescent cells in the aging stem cell niche. Stem Cell Rep. 17, 259–275 (2022).
doi: 10.1016/j.stemcr.2021.12.010
Lu, L. et al. Engineered microparticles for treatment of murine brain metastasis by reprograming tumor microenvironment and inhibiting MAPK pathway. Adv. Sci. 10, e2206212 (2023).
doi: 10.1002/advs.202206212
Huang, Z. et al. HAUSP stabilizes SOX2 through deubiquitination to maintain self-renewal and tumorigenic potential of glioma stem cells. Preprint at bioRxiv https://doi.org/10.1101/2021.06.09.447550 (2021).
Kim, J. et al. Evolutionarily conserved regulators of tau identify targets for new therapies. Neuron 111, 824–838.e827 (2023).
doi: 10.1016/j.neuron.2022.12.012
pubmed: 36610398
Vilgelm, A. E. et al. Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Res. 75, 181–193 (2015).
doi: 10.1158/0008-5472.CAN-14-2405
pubmed: 25398437
Jeon, O. H. et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat. Med. 23, 775–781 (2017).
doi: 10.1038/nm.4324
pubmed: 28436958
pmcid: 5785239
Mannarino, M. et al. Senolytic combination treatment is more potent than single drugs in reducing inflammatory and senescence burden in cells from painful degenerating IVDs. Biomolecules 13, 1257 (2023).
doi: 10.3390/biom13081257
pubmed: 37627322
pmcid: 10452201
Grillone, A. et al. Nutlin-loaded magnetic solid lipid nanoparticles for targeted glioblastoma treatment. Nanomedicine 14, 727–752 (2018).
doi: 10.2217/nnm-2018-0436
pubmed: 30574827
Goldwirt, L. et al. Brain distribution of the MDM2 inhibitor, RG7112: Single dose escalation and repeated doses studies. J. Clin. Oncol. 33, e13582 (2015).
doi: 10.1200/jco.2015.33.15_suppl.e13582
Homan, M. J. et al. Panobinostat penetrates the blood-brain barrier and achieves effective brain concentrations in a murine model. Cancer Chemother. Pharmacol. 88, 555–562 (2021).
doi: 10.1007/s00280-021-04313-2
pubmed: 34115161
pmcid: 8896403
Chien, Y. et al. Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev. 25, 2125–2136 (2011).
doi: 10.1101/gad.17276711
pubmed: 21979375
pmcid: 3205583
Ruan, Y. et al. Kainic acid Induces production and aggregation of amyloid β-protein and memory deficits by activating inflammasomes in NLRP3- and NF-κB-stimulated pathways. Aging 11, 3795–3810 (2019).
doi: 10.18632/aging.102017
pubmed: 31182681
pmcid: 6594814
Yang, T. et al. A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization. Acta Pharm. Sin. B 12, 2658–2671 (2022).
doi: 10.1016/j.apsb.2022.02.009
pubmed: 35755286
pmcid: 9214068
Kasinski, A. L. et al. Inhibition of IκB kinase-nuclear factor-κB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol. Pharmacol. 74, 654–661 (2008).
doi: 10.1124/mol.108.046201
pubmed: 18577686
Dou, X. et al. Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: computational simulation, biological evaluation and cancer combinational chemotherapy study. Eur. J. Med. Chem. 233, 114196 (2022).
doi: 10.1016/j.ejmech.2022.114196
pubmed: 35231830
Chwastek, J., Jantas, D. & Lasoń, W. The ATM kinase inhibitor KU-55933 provides neuroprotection against hydrogen peroxide-induced cell damage via a γH2AX/p-p53/caspase-3-independent mechanism: inhibition of calpain and cathepsin D. Int. J. Biochem. Cell Biol. 87, 38–53 (2017).
doi: 10.1016/j.biocel.2017.03.015
pubmed: 28341201
Liu, J. et al. Piperlongumine restores the balance of autophagy and apoptosis by increasing BCL2 phosphorylation in rotenone-induced Parkinson disease models. Autophagy 14, 845–861 (2018).
doi: 10.1080/15548627.2017.1390636
pubmed: 29433359
pmcid: 6070010
Go, J. et al. Piperlongumine decreases cognitive impairment and improves hippocampal function in aged mice. Int. J. Mol. Med. 42, 1875–1884 (2018).
pubmed: 30066827
pmcid: 6108885
Doan, L. et al. Targeted senolytic prodrug is well tolerated and results in amelioration of frailty, muscle regeneration and cognitive functions in geriatric mice. Preprint at Res. Sq. https://www.researchsquare.com/article/rs-92962/v1 (2020).
Cai, Y. et al. Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. Cell Res. 30, 574–589 (2020).
doi: 10.1038/s41422-020-0314-9
pubmed: 32341413
pmcid: 7184167
Rutigliano, G., Stazi, M., Arancio, O., Watterson, D. M. & Origlia, N. An isoform-selective p38α mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer’s disease. Neurobiol. Aging 70, 86–91 (2018).
doi: 10.1016/j.neurobiolaging.2018.06.006
pubmed: 30007168
pmcid: 6119125
Roy, S. M. et al. Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer’s disease mouse models. ACS Chem. Neurosci. 6, 666–680 (2015).
doi: 10.1021/acschemneuro.5b00002
pubmed: 25676389
Haile, W. B. et al. The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model. Neurobiol. Dis. 92, 137–143 (2016).
doi: 10.1016/j.nbd.2016.02.007
pubmed: 26851503
pmcid: 4907871
Roy, S. M. et al. A selective and brain penetrant p38αMAPK inhibitor candidate for neurologic and neuropsychiatric disorders that attenuates neuroinflammation and cognitive dysfunction. J. Med. Chem. 62, 5298–5311 (2019).
doi: 10.1021/acs.jmedchem.9b00058
pubmed: 30978288
pmcid: 6580366
Lee, H.-C. et al. Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice. Sci. Rep. 11, 3847 (2021).
doi: 10.1038/s41598-021-83222-z
pubmed: 33589712
pmcid: 7884429
Peng, J. et al. Ruxolitinib, a promising therapeutic candidate for traumatic brain injury through maintaining the homeostasis of cathepsin B. Exp. Neurol. 363, 114347 (2023).
doi: 10.1016/j.expneurol.2023.114347
pubmed: 36813222
Gong, N. et al. The aspirin metabolite salicylate enhances neuronal excitation in rat hippocampal CA1 area through reducing GABAergic inhibition. Neuropharmacology 54, 454–463 (2008).
doi: 10.1016/j.neuropharm.2007.10.017
pubmed: 18078964
Laukkanen, S. et al. In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL. Blood Cancer J. 7, e604 (2017).
doi: 10.1038/bcj.2017.87
pubmed: 28885610
pmcid: 5709756
Choi, K. M. et al. Activity-based protein profiling reveals potential dasatinib targets in gastric cancer. Int. J. Mol. Sci. 21, 9276 (2020).
doi: 10.3390/ijms21239276
pubmed: 33291786
pmcid: 7729964
Almatroodi, S. A. et al. Potential therapeutic targets of quercetin, a plant flavonol, and its role in the therapy of various types of cancer through the modulation of various cell signaling pathways. Molecules 26, 1315 (2021).
doi: 10.3390/molecules26051315
pubmed: 33804548
pmcid: 7957552
Jakaria, M. et al. Potential therapeutic targets of quercetin and its derivatives: its role in the therapy of cognitive impairment. J. Clin. Med. 8, 1789 (2019).
doi: 10.3390/jcm8111789
pubmed: 31717708
pmcid: 6912580